Optimum Platelet Inhibition After Coronary Bypass Surgery
Not Applicable
Completed
- Conditions
- Ischemic Heart Disease
- Registration Number
- NCT00262275
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Brief Summary
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.
Exclusion Criteria
Preoperative exclusion criteria:
- patients who are have not stopped aspirin 7 days prior to surgery
- patients on concomitant NSAIDS
- patients with a previous history platelet disorders, splenectomy or haematological disorders
- patients with aspirin induced asthma
- patients with any contraindications to aspirin (GI bleed)
- patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
- Women of childbearing potential
- Patients of less than 18 years
- If informed consent cannot be obtained
- If for any reason the consultant surgeon or anaesthetist deems it to be appropriate
Operative exclusion criteria:
• Concomitant procedures
Postoperative exclusion criteria:
- patients who receive platelet transfusion
- patients who receive NSAIDS
- requirement for intra aortic balloon pump support
- failure of extubation within 24 hours
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Papworth Hospital
🇬🇧Cambridge, United Kingdom